These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 16908270

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation.
    Tzakis AG, Kato T, Nishida S, Levi DM, Madariaga JR, Nery JR, Mittal N, Regev A, Cantwell P, Gyamfi A, Weppler D, Miller J, Tryphonopoulos P, Ruiz P.
    Transplantation; 2003 Apr 27; 75(8):1227-31. PubMed ID: 12717207
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period.
    Zanfi C, Lauro A, Cescon M, Dazzi A, Ercolani G, Grazi GL, Zanello M, Vivarelli M, Del Gaudio M, Ravaioli M, Cucchetti A, Vetrone G, Tuci F, Di Gioia P, Lazzarotto T, D'Errico A, Bagni A, Faenza S, Siniscalchi A, Pironi L, Pinna AD.
    Transplant Proc; 2010 Apr 27; 42(1):35-8. PubMed ID: 20172276
    [Abstract] [Full Text] [Related]

  • 5. Campath-1H immunosuppressive therapy reduces incidence and intensity of acute rejection in intestinal and multivisceral transplantation.
    Garcia M, Weppler D, Mittal N, Nishida S, Kato T, Tzakis A, Ruiz P.
    Transplant Proc; 2004 Mar 27; 36(2):323-4. PubMed ID: 15050146
    [Abstract] [Full Text] [Related]

  • 6. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
    Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H.
    Bone Marrow Transplant; 2000 Jul 27; 26(1):69-76. PubMed ID: 10918407
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation.
    Tzakis AG, Kato T, Nishida S, Levi DM, Tryphonopoulos P, Madariaga JR, De Faria W, Nery JR, Regev A, Vianna R, Miller J, Esquenazi V, Weppler D, Ruiz P.
    Transplantation; 2003 May 15; 75(9):1512-7. PubMed ID: 12792506
    [Abstract] [Full Text] [Related]

  • 8. Pediatric liver transplant with Campath 1H induction--Preliminary report.
    Kato T, Selvaggi G, Panagiotis T, Hernandez E, McLaughlin G, Moon J, Nishida S, Levi D, Thompson J, Halliday N, Ruiz P, Tzakis A.
    Transplant Proc; 2006 Dec 15; 38(10):3609-11. PubMed ID: 17175346
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Campath induction for kidney transplantation: report of 297 cases.
    Ortiz J, Palma-Vargas J, Wright F, Bingaman A, Agha I, Rosenblatt S, Foster P.
    Transplantation; 2008 Jun 15; 85(11):1550-6. PubMed ID: 18551058
    [Abstract] [Full Text] [Related]

  • 12. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.
    Transplant Proc; 2005 Dec 15; 37(10):4235-40. PubMed ID: 16387087
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression.
    Baez Y, Giron F, Niño-Murcia A, Rodríguez J, Salcedo S.
    Transplant Proc; 2008 Apr 15; 40(3):697-9. PubMed ID: 18454990
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 15; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 20. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.
    Transplant Proc; 2010 Mar 15; 42(1):29-34. PubMed ID: 20172275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.